Zondan has entered into a collaboration agreement to incorporate Masimo's signal extraction technology (SET) and rainbow SET pulse co-oximetry into its N Series of patient monitors.
The N Series of patient monitors are designed to address various applications in multiple specialty care areas such as the general ward, EMS/transport, NICU, ICU/CCUs, and operating rooms.
Masimo's SET performs measurements through motion and low perfusion in the NICU unit and helps clinicians to reduce retinopathy of prematurity, and detect critical congenital heart disease in newborns.
Masimo said the SET delivers accurate measurements of a patient's true oxygenation status by using patented signal processing technologies including parallel engines and adaptive filters.
In higher acuity patient care areas such as the ICU/CCU or OR, Zondan patient monitors will incorporate the Masimo's rainbow technology including noninvasive and continuous measurements for total hemoglobin, oxygen content, carboxyhemoglobin, methemoglobin, Pleth Variability Index, and rainbow Acoustic Monitoring.
Zondan general manager Feng Li said, "With limited access to healthcare in parts of China, and advanced monitoring technologies in short supply within many healthcare facilities, the Chinese government is investing heavily in innovative companies and technologies that will advance access to affordable, high quality patient care."
Masimo OEM business and business development president Rick Fishel said the company's mission is to improve patient outcomes and reduce the cost of care by taking noninvasive monitoring to new sites and applications.
"Zondan has a shared vision for bringing innovative, noninvasive, real-time technologies to the bedside so that caregivers may make informed clinical decisions earlier," Fishel added.
